Latest Breaking News On - Alexandre tokay - Page 1 : comparemela.com

Vect-Horus Enters Exclusive License Agreement with Ionis Pharmaceuticals to Advance Systemic Delivery of RNA-Targeted Medicines for Neurological Diseases

Vect-Horus Enters Exclusive License Agreement with Ionis Pharmaceuticals to Advance Systemic Delivery of RNA-Targeted Medicines for Neurological Diseases
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Stefan klotterErice swayzeMichel khrestchatiskyAlexandre tokayInstitute for neurophysiopathologyAix marseille universityIonis pharmaceuticals incIonis pharmaceuticalsDie performance strategieAssets sie

Ionis Pharmaceuticals (IONS) and Vect-Horus Enter Exclusive License Agreement to Advance Systemic Delivery of RNA-Targeted Medicines for Neurological Diseases

Ionis Pharmaceuticals (IONS) and Vect-Horus Enter Exclusive License Agreement to Advance Systemic Delivery of RNA-Targeted Medicines for Neurological Diseases
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Erice swayzeAlexandre tokayMichel khrestchatiskyIonis pharmaceuticals incInstitute for neurophysiopathologyAix marseille universityIonis pharmaceuticals

Vect-Horus Strengthens its Scientific Advisory Board with the Appointment of Pr Xavier Declèves

Vect-Horus Strengthens its Scientific Advisory Board with the Appointment of Pr Xavier Declèves
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

France generalAlexandre tokayMichel khrestchatiskyInstitute for neurophysiopathologyCochin universityAix marseille universityResearch viceDepartment of pharmacologyXavier declResearch vice deanBlood brain barrierBrain pathophysiologyChief scientific officerVect horus advisory board

Vect-Horus lands licensing pact with Novo Nordisk to improve drug delivery

The French biotech company Vect-Horus has licensed its technology to the Danish big pharma Novo Nordisk to deliver drug cargoes to undisclosed disease targets in three programs.

Alexandre tokayBrian vandahlDrug administrationNovo nordiskMarkets amp regulationsEmerging marketsNovo nordisk pharmatechLicensing agreementPharmaceutical industryDrug deliveryDrug delivery systems

Vect-Horus Enters Exclusive License Agreement with Novo Nordisk to Develop Targeted Therapeutics

MARSEILLE, France, October 30, 2023 Vect-Horus announced it has entered into a global license agreement with Novo Nordisk A/S.

Brian vandahlAlexandre tokayNovo nordiskMichel khrestchatiskyGlobal research technologies at novo nordiskAix marseille universityInstitute for neurophysiopathologySenior vice presidentGlobal research technologiesTherapeutic moleculesEct horusGlobal research technologies